Slimming medications may make you blind! – Iranian and world news

In one of the newly published investigations in the magazine JAMAData for about 1.5 million people were investigated and it was found that in people with diabetes who take drugs such as samglytide or throat, the risk of opaque nerve disorders increased.

The study specifically refers to a rare but destructive disease called “anterior anterior neuropathic neuropathic neuropathy” (Naion). The disease causes the bloodstream to the optic nerve to decrease or block, which can lead to an eye stroke. Patients usually notice the disease when they have lost their eyesight. The important thing is that treatment has not been known for this disease so far.

Earlier, a study showed that every 6,000 people are likely to develop naion due to Samgotide consumption. But in a recent study, out of the 6,000 patients with type 2 diabetes who received samaglotide or tirepathids, 4 people (ie about one out of every 2 people) were infected with Naion.

During two years of follow -up, the researchers identified 3 cases of NaION in the consumer consumer group of Samglotide or Tirzepatide. Also, the other 5 patients had various optic nerve disorders.

Another large study conducted on 6,000 people published in the same magazine found that GLP-RA weight loss drugs were associated with an increased risk of diabetic retinopathy (damage to retinal blood vessels).

However, the researchers emphasized that participants who took GLP-1 drugs had less threatening visual complications than those who received diabetes and had less need for invasive eye treatments.

Although the overall risk of such low diseases is assessed, the researchers have recommended that patients be more accurate. They also called for further long -term research to clarify how these drugs affect eye health.